Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | FDPS | P14324 | 1/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987445 | 1.00 | MAOB (0.67) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL19961012 | 1.00 | MAOB (0.67) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL6980423 | 0.90 | FDPS (0.64) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL6980418 | 0.90 | FDPS (0.64) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL30268639 | 0.89 | MAOB (0.55) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL10080272 | 0.87 | EPHX2 (0.63) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL6985126 | 0.86 | TTR (0.58) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL6985121 | 0.86 | TTR (0.58) | MAOBFDPSMCL1BACE1PKM | |
| SCHEMBL3492139 | 0.85 | MAOB (0.56) | MAOBFDPSMCL1PKMGAA | |
| SCHEMBL6986048 | 0.85 | MAOB (0.56) | MAOBFDPSMCL1PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383912-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | PRG S&TECH INC. (KR) | 2024-11-21 | — | — | US | claimed |
| EP-4414367-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | PRG S&Tech Inc. (KR) | 2024-08-14 | — | — | EP | claimed |
| WO-2023058875-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | (주)피알지에스앤텍 | 2023-04-13 | — | — | WO | claimed |
| US-20240383912-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | PRG S&TECH INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| EP-4414367-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | PRG S&Tech Inc. (KR) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023058875-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | (주)피알지에스앤텍 | 2023-04-13 | — | — | WO | disclosed |
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0569380-A1 | ACRIDINE DERIVATIVES. | GLAXO LAB SA (FR) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012132-A1 | ACRIDINE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383912-A1 | NOVEL METHOD FOR SYNTHESIZING DECURSIN DERIVATIVE | PRTN3, PARG, PLA2G12B | MAOB 527/4885FDPS 2132/4885MCL1 4292/4885 |
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | MAOB 2164/4885FDPS 296/4885MCL1 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.